Adaptive Biotechnologies turns its first profit, beating expectations

As seen on the 24/7 Wall St. homepage on November 4, 2026.

ADPT Adaptive Biotechnologies
Q3 2026
EPS
$0.02
est -$0.10 +120.9%
Revenue
$84M
est $72M +17.2%

First profitable quarter after years of losses, and it arrived earlier than management guided. clonoSEQ tests delivered rose 46% to 39,587, lifting full-year MRD revenue guidance.

Continue ReadingShow less

Adaptive Biotechnologies posted GAAP earnings per share of $0.02 in Q3 2026, flipping to profitability ahead of management's own schedule and beating expectations against a consensus estimate of negative $0.10. The quarter turned a GAAP profit even after restructuring charges and zero revenue from the now-lapsed Genentech Agreement.

Revenue of $83.90 million beat the consensus, meeting expectations on the top line even as total revenue fell about 11% year over year on the absence of Genentech Agreement revenue, with underlying revenue rising 39%. The MRD segment, which houses the company's clonoSEQ cancer-detection business, grew 28%.

clonoSEQ tests delivered jumped 46% to 39,587 in the quarter, the volume driver behind higher MRD segment adjusted EBITDA. Free cash flow turned positive, R&D expense fell, and interest expense dropped after the company extinguished its revenue interest liability.

Sponsored

On the strength of that volume momentum, management raised full-year 2026 MRD revenue guidance to $276 million to $286 million, up from the prior range of $268 million to $278 million, implying 30% to 35% annual growth. Total operating expense guidance was tightened to approximately $350 million from the previous $350 million to $355 million range.

Two clinical-policy developments extend clonoSEQ's runway further. The NCCN established a dedicated framework for MRD assessment in multiple myeloma, including annual testing during maintenance, while the International Myeloma Working Group introduced the first definition of cure for multiple myeloma, requiring sustained MRD negativity at one-in-a-million sensitivity. Both shifts expand the addressable population for routine MRD testing. Adaptive also submitted a technical assessment to MolDX seeking an additional Medicare coverage bundle for clonoSEQ maintenance testing in multiple myeloma, a reimbursement decision that investors will want to follow closely.

Mentioned: ADPT